Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Tahir Masud1, Michael McClung2, Piet Geusens3
1Nottingham University Hospitals NHS Trust, Nottingham, UK; 2Oregon Osteoporosis Center, Portland, Oregon, USA; 3Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, Belgium
Background: There is limited evidence to support the efficacy of current pharmaceutical agents in reducing the risk of hip fracture in older postmenopausal women with established osteoporosis.
Objective: To clarify the efficacy of risedronate in reducing the risk of hip fracture in elderly postmenopausal women aged ≥70 years with established osteoporosis, i.e., those with bone mineral density-defined osteoporosis and a prevalent vertebral fracture.
Methods: Post hoc analysis of the Hip Intervention Program (HIP) study, a randomized controlled trial comparing risedronate with placebo for reducing the risk of hip fracture in elderly women. Women aged 70 to 100 years with established osteoporosis (baseline femoral neck T-score ≤ −2.5 and ≥ 1 prior vertebral fracture) were included. The main outcome measure was 3-year hip fracture incidence in the risedronate and placebo groups.
Results: A total of 1656 women met the inclusion criteria. After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32–0.91; P = 0.019).
Conclusion: Risedronate significantly reduced the risk of hip fracture in women aged up to 100 years with established osteoporosis.
Keywords: osteoporosis, postmenopausal, hip fracture, risedronate
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.